Atlas Trials

Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing

Clinical trial NCT02749292 · TERMINATED

Trial details

NCT number
NCT02749292
Sponsor
Massachusetts General Hospital
Status
TERMINATED
Phase
Phase 4
Study type
INTERVENTIONAL
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Start date
2016-06-01
Primary completion
2022-01-31
Enrollment
115

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.